Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07403214 · ClinicalTrials.gov registry record
A Real-world Study of Disease-modifying Therapy Treatment Outcomes in Patients With Spinal Muscular Atrophy
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 4,805
- Enrollment target
NCT07403214 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 4,805 participants.
The verdict
NCT07403214 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 4,805 participants
- Enrollment target
Study Summary
The aim of this study was to evaluate treatment patterns, SMA-related complications and services, and all-cause medical encounters of patients with SMA receiving multiple DMTs in the real world. The DMTs included onasemnogene abeparvovec-xioi (OA), nusinersen, and risdiplam. This study was conducted using data from the Komodo Health Research Database (KRD+) between 01 January 2016 and 31 October 2024.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,805 participants |
| Start Date | 2025-06-04 |
| Est. Completion | 2025-06-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07403214
The ClinicalTrials.gov registry entry for NCT07403214 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 4,805 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT07403214 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07403214 about?
NCT07403214 is a clinical study titled "A Real-world Study of Disease-modifying Therapy Treatment Outcomes in Patients With Spinal Muscular Atrophy". The aim of this study was to evaluate treatment patterns, SMA-related complications and services, and all-cause medical encounters of patients with SMA receiving multiple DMTs in the real world. The DMTs included onasemnogene abeparvovec-xioi (OA), nusinersen, and risdiplam. This study was conducted...
What is the current status of trial NCT07403214?
This trial is currently completed. The enrollment target is 4,805 participants. The study started on 2025-06-04. Estimated completion is 2025-06-30.
Who is sponsoring clinical trial NCT07403214?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.